β-blockers interfere with cell homing receptors and regulatory proteins in a model of spontaneously hypertensive rats

Cardiovascular Therapeutics
Bruna EibelMelissa Medeiros Markoski

Abstract

To examine the interference of β-blockers with the chemokine stromal cell-derived factor-1 (SDF-1) found in cell homing receptors, C-X-C chemokine receptor type 4 (CXCR-4) and CXCR-7, and regulatory proteins of homing pathways, we administered atenolol, carvedilol, metoprolol, and propranolol for 30 days using an orogastric tube to hypertensive rats. We collected blood samples before and after treatment and quantified the levels of SDF-1 with enzyme-linked immunosorbent assay (ELISA). On day 30 of treatment, the spontaneously hypertensive rats (SHR) were euthanized, and heart, liver, lung, and kidney tissues were biopsied. Proteins were isolated for determining the expression of CXCR-4, CXCR-7, GRK-2 (G protein-coupled receptors kinase 2), β-arrestins (β1-AR and β2-AR), and nuclear factor kappa B (NFκB). We found that the study drugs modulated these proteins, and metoprolol and propranolol strongly affected the expression of β1-AR (P = .0102) and β2-AR (P = .0034). β-blockers modulated tissue expression of the proteins and their interactions following 30 days of treatment. It evidences that this class of drugs can interfere with proteins of cell homing pathways.

References

Nov 15, 1986·Postgraduate Medicine·E D Frohlich
Mar 1, 1981·Circulation Research·N C Trippodo, E D Frohlich
Sep 5, 2002·Nature Reviews. Molecular Cell Biology·Kristen L PierceRobert J Lefkowitz
Nov 9, 2004·Lancet·Bo CarlbergLars Hjalmar Lindholm
Jul 17, 2007·Cancer Letters·Dayanidhi RamanAnn Richmond
Sep 6, 2007·The Journal of Clinical Investigation·Takahisa NomaHoward A Rockman
Apr 26, 2008·Heart Failure Reviews·Jaekyu Shin, Julie A Johnson
Jun 25, 2009·Journal of Molecular Modeling·Anwar Rayan
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Sudarshan RajagopalRobert J Lefkowitz
Feb 18, 2010·PloS One·Ulrike NaumannMarcus Thelen
Feb 26, 2010·International Archives of Medicine·José R CisternasLuiz Carlos de Abreu
Jul 2, 2010·British Journal of Pharmacology·Petronila PenelaFederico Mayor
Aug 24, 2010·Journal of Cardiovascular Pharmacology·Thomas J LaRoccaSima T Tarzami
Jul 23, 2011·Circulation Research·Stephen L Belmonte, Burns C Blaxall
Dec 14, 2011·Expert Review of Cardiovascular Therapy·James J DiNicolantonio, Daniel G Hackam
Jun 29, 2012·The Journal of Pharmacology and Experimental Therapeutics·Fatemat HassanMahmood Khan
Nov 16, 2012·Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology·Hai-Xiao ZouYi-Fang Zhao
Jan 8, 2013·The American Journal of Cardiology·James J DiNicolantonioJames H O'Keefe
Feb 15, 2013·Nature·A J VenkatakrishnanM Madan Babu
Apr 8, 2014·Antioxidants & Redox Signaling·Zheng Maggie HuangWalter J Koch
Feb 18, 2016·Stem Cells International·Maximiliano I SchaunMelissa M Markoski

❮ Previous
Next ❯

Citations

Jul 7, 2019·Gene Therapy·Roberto Tofani Sant'AnnaRenato Abdala Karam Kalil

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.